TAK-861 (Oveporexton): A Landmark Oral Orexin Receptor 2 Agonist for Narcolepsy Type 1

Narcolepsy type 1 has long been treated with medications that manage symptoms rather than address the disease itself. That may be about to change. Oveporexton tak 861, an investigational oral orexin receptor 2 agonist, has delivered compelling Phase 3 results and is now under priority review by the FDA, positioning it as the first orexin therapy candidate to reach this regulatory milestone for narcolepsy type 1.

Key Takeaways

• Oveporexton (TAK-861) is an investigational oral orexin receptor 2-selective agonist developed by Takeda Pharmaceutical Company to treat narcolepsy type 1 by addressing the underlying orexin deficiency that drives the disease.

• The FirstLight and RadiantLight Phase 3 clinical trials reported positive results across all primary and secondary endpoints, including significant improvements in excessive daytime sleepiness, weekly cataplexy rate, and quality of life over 12 weeks.

• The FDA granted priority review for oveporexton's new drug application, with a PDUFA target decision date in Q3 2026; regulatory submissions are also underway in Japan, China, and other markets.

• Current standards of care such as stimulants and sodium oxybate primarily relieve narcolepsy symptoms without addressing the root cause, while oveporexton aims to restore orexin signaling and potentially transform the current treatment paradigm for NT1.

What Is TAK-861 (Oveporexton)?

TAK-861, also known as oveporexton, is a next-generation orexin receptor 2 (OX2R)–selective agonist designed to treat sleep disorders rooted in orexin deficiency. It represents one of Takeda's groundbreaking efforts targeting the orexin pathway with an oral small molecule.

• Oveporexton is an investigational small-molecule drug taken orally that selectively stimulates the orexin receptor 2 pathway. In narcolepsy type 1, orexin-producing neurons in the lateral hypothalamus are destroyed, leading to near-complete loss of orexin signaling. TAK-861 is designed to replace that missing signal.

• Orexin (also called hypocretin) neurons regulate wakefulness, suppress inappropriate REM sleep, and stabilize transitions between sleep stages. Loss of these neurons is the hallmark of NT1 and the underlying cause of its characteristic symptoms: excessive daytime sleepiness and cataplexy, the sudden loss of muscle tone triggered by strong emotions.

• By activating OX2R, oveporexton promotes wakefulness and stabilizes sleep-wake transitions without relying on classical stimulants or GABAergic sedation. Preclinical data show approximately 3,000-fold selectivity for OX2R over OX1R, with an EC₅₀ of roughly 2.5 nM.

• TAK-861 may serve as a disease-modifying treatment rather than symptomatic management. If approved, TAK-861 may significantly change treatment practices for narcolepsy type 1. It has been highlighted as a landmark oveporexton therapy candidate in key peer-reviewed publications, with orexin data published in high-impact journals such as Nature Medicine and clinical formats comparable to those in the New England Journal of Medicine.

Orexin Biology and the Rationale for Orexin Receptor 2 Agonists

Understanding why an oral orexin receptor 2 agonist matters requires a brief look at the neuroscience behind narcolepsy. Orexin biology sits at the center of wake-sleep regulation, and its disruption explains nearly every symptom of NT1.

• Orexin peptides and wakefulness: Orexin A and orexin B, produced by neurons in the lateral hypothalamus, maintain continuous wakefulness during the day, regulate REM sleep timing at night, and link emotional arousal with muscle tone. When these neurons are lost, the brain can no longer reliably separate wakefulness from sleep.

• OX1R vs. OX2R: The orexin receptor system includes two subtypes. OX2R is particularly critical for stable wakefulness and REM sleep suppression-animal models lacking OX2R replicate core NT1 features more faithfully than OX1R knockouts. This makes OX2R the primary target for orexin therapy in NT1.

• Orexin levels in NT1: In narcolepsy type 1, cerebrospinal fluid orexin levels are typically very low or undetectable (below 110 pg/mL), resulting in excessive daytime sleepiness, cataplexy, fragmented nighttime sleep, hallucinations, and sleep paralysis. Orexin biomarkers such as CSF hypocretin-1 and HLA-DQB1*06:02 status help confirm diagnosis.

• Downstream vs. upstream treatments: Current therapies are "downstream"-they manage symptoms without replacing missing orexin. Sodium oxybate consolidates nighttime sleep via GABAergic mechanisms. Stimulants like modafinil increase monoaminergic tone to combat sleepiness. Antidepressants partially suppress cataplexy. None of these address the underlying orexin deficiency. Orexin agonists like TAK-861 work "upstream," directly restoring the deficient signal.

• Preclinical foundation: Orexin data from preclinical models demonstrated that OX2R agonists could restore wakefulness, reduce cataplexy-like episodes, and normalize sleep architecture in orexin-deficient animals, providing the scientific foundation for TAK-861 development.

Clinical Development of TAK-861: From Preclinical Data to Landmark Oveporexton Trials

The path from early orexin knockout mouse studies in the early 2000s to a viable oral OX2R agonist has been long and marked by both setbacks and breakthroughs. TAK-861 emerged from lessons learned with earlier compounds in Takeda's orexin franchise.

• Preclinical potency and selectivity: TAK-861 demonstrated potent OX2R agonism with nanomolar EC₅₀ values in calcium mobilization and IP1 accumulation assays, robust wake-promoting effects in wild-type mice and cynomolgus monkeys, and minimal off-target activity across more than 100 receptor and channel panels. The minimum effective dose in mice was approximately 1 mg/kg.

• Publication milestones: TAK-861's pharmacology and translational safety profile were detailed in Nature Medicine, establishing its credentials in the sleep sciences community and among presenting authors at major conferences.

• Earlier OX2R agonist setbacks: TAK-994, an earlier oral OX2R agonist, showed efficacy but was discontinued due to drug-induced liver injury. Danavorexton (TAK-925) required parenteral administration. TAK-861 was specifically engineered for higher potency at lower doses and improved hepatic safety.

• Phase 1/2 data: In Phase 1, healthy individuals showed dose-dependent increases in mean sleep latency on the Maintenance of Wakefulness Test with no severe adverse events. The Phase 2b trial in NT1 patients demonstrated dose-dependent improvements in sleep latency, Epworth Sleepiness Scale scores, and weekly cataplexy rate reductions over 8 weeks. Phase 2b and Phase 3 trials have demonstrated remarkable efficacy in treating narcolepsy type 1 symptoms. TAK-861 has shown significant potential in improving alertness and reducing daytime sleepiness in trials.

• Phase 3 program launch: TAK-861 is currently undergoing Phase III clinical studies for narcolepsy type 1 among other hypersomnia disorders. The program centers on two pivotal placebo controlled studies-FirstLight and RadiantLight-initiated around 2023–2024. By mid-2025, Takeda announces positive results from both trials, clearing the path for regulatory filings.

FirstLight and RadiantLight Phase 3 Studies in Narcolepsy Type 1

FirstLight and RadiantLight are the pivotal global Phase 3 trials evaluating oveporexton in adults with narcolepsy type 1. Together, these clinical studies led to the regulatory submissions now under review worldwide.

• Study design: Both were randomized, double-blind, placebo-controlled, multicenter trials enrolling adults diagnosed per International Classification of Sleep Disorders (ICSD-3) criteria, supported by polysomnography/MSLT, CSF orexin measurement, or HLA genotyping. The FirstLight study enrolled 168 participants with narcolepsy type 1. The RadiantLight study enrolled 105 participants with narcolepsy type 1. Both studies were conducted in 19 countries over 12 weeks.

• Dosing regimens: In the firstlight phase 3 trial, participants received either 1 mg BID, 2 mg BID oveporexton, or placebo. RadiantLight tested 2 mg BID versus placebo. All dosing was oral, twice daily.

• Primary endpoint: The primary endpoint was change from baseline to week 12 in mean sleep latency on the Maintenance of Wakefulness Test (MWT), a validated objective measure of the ability to maintain attention and stay awake.

• Secondary endpoints: Major secondary endpoints included the Epworth Sleepiness Scale (ESS) total score, weekly cataplexy rate, symptom severity scales (Narcolepsy Severity Scale–Clinician Tool, Patient Global Impression of Change), and health-related quality of life measures (SF-36, EQ-5D-5L).

• Broader assessment: The trials also evaluated nighttime sleep architecture, REM intrusions, hallucinations, sleep paralysis, and cognitive functioning-capturing both daytime and nocturnal manifestations of NT1. Over 95% of participants completed their treatment cycles, reflecting strong tolerability and engagement. New York City has several major academic medical centers that are involved in the clinical trials of TAK-861, alongside sites across Europe, Asia, and Latin America.

Efficacy Results: Wakefulness, Cataplexy, and Quality of Life

The Phase 3 oveporexton program delivered statistically significant improvement across every prespecified endpoint. Here is what the data showed across the core symptom domains.

Wakefulness

• Participants treated with 1 mg and 2 mg BID oveporexton achieved clinically meaningful increases in wakefulness test latency by week 12. A substantial proportion of those on 2 mg BID reached the normative range for wakefulness (MWT ≥20 minutes), a threshold typically seen in healthy individuals. Participants achieved MWT times within normative range after treatment.

• Oveporexton showed statistically significant improvements in excessive daytime sleepiness. Approximately 85% of participants reached ESS scores comparable to healthy individuals (ESS ≤10), placing their daytime sleepiness and cataplexy burden well within the normal range observed in the general population.

Cataplexy

• Weekly cataplexy rate dropped over 80% from baseline with oveporexton compared to placebo. This reduction covered both complete and partial cataplexy attacks-the defining symptom of NT1, characterized by sudden loss of muscle tone triggered by strong emotions such as laughter or surprise.

• Median cataplexy free days increased substantially, rising from virtually zero at baseline to roughly 4–5 per week at week 12. Patient diaries confirmed that emotionally triggered episodes of muscle weakness became markedly less frequent.

Symptom Severity and Quality of Life

• More than 70% of treated participants shifted into the "mild" category on the Narcolepsy Severity Scale–Clinician Tool (NSS-CT), and more than 90% reported "much improved" or "very much improved" on global impression scales-reflecting broad symptom relief across overall narcolepsy symptoms.

• Patients reported improved functioning and quality of life during trials of TAK-861. SF-36 and EQ-5D-5L domain scores for vitality, social functioning, and role-emotional moved toward normative values, indicating real benefit in daily life functions. Cognitive measures also improved: approximately 70% of treated participants reported no significant cognitive difficulties, compared with roughly 15% in the placebo group.

• Data presented at the World Sleep Congress confirmed significant improvements in nighttime sleep quality, with reductions in hallucinations, sleep paralysis, and disturbed sleep patterns.

Safety, Tolerability, and Comparison With Existing NT1 Treatments

Safety and tolerability were carefully evaluated across the 12-week Phase 3 period and in ongoing open-label extensions. Oveporexton demonstrated a well-tolerated safety profile in phase 3 studies, consistent with earlier clinical studies in the program.

• No serious treatment-related adverse events were reported in either pivotal trial during the double-blind period.

• The most common adverse events were insomnia and urinary urgency, along with urinary frequency and mild headache. Most adverse events were mild or moderate in severity and often transient, resolving without dose modification.

• Over 95% of participants completed their treatment cycles in trials, and discontinuation rates due to common adverse events were low-reinforcing the drug's tolerability and supporting long-term use potential.

• Oveporexton was generally well tolerated, with most treatment related side effects not requiring intervention. The safety profile was broadly consistent with prior Phase 2 orexin data.

How Does Oveporexton Compare With Current NT1 Therapies?

Oveporexton, as an oral orexin receptor 2–selective agonist, directly targets the orexin receptor deficit rather than broadly stimulating the central nervous system-a fundamentally different approach from every currently approved treatment option.

Long-term safety monitoring, including metabolic, cardiovascular, and neuropsychiatric outcomes, is ongoing through open-label extension studies and planned post-marketing pharmacovigilance, in accordance with applicable laws and regulatory guidance.

Regulatory Status, Publications, and Future Directions

TAK-861 has moved rapidly from late-stage trials to global regulatory review. Takeda presents orexin data at an accelerating pace, and the regulatory timeline reflects the urgency of unmet need in NT1.

• The U.S. FDA accepted the New Drug Application for oveporexton and granted priority review, with a PDUFA target date in Q3 2026. Parallel filings are underway in Japan, China, and other major markets.

• Detailed Phase 3 data are being prepared for publication in high-impact peer-reviewed journals, with formats comparable to those in the New England Journal of Medicine. Interim orexin data have already appeared in journals such as Nature Medicine, and the principal investigator teams from both trials have presented at the World Sleep Congress and SLEEP 2026.

• Takeda's broader orexin franchise includes other orexin agonists in development. TAK-360, for example, is being studied for narcolepsy type 2 and idiopathic hypersomnia-conditions where the role of orexin receptor agonism is still being defined.

• Future research will explore real-world effectiveness, optimal dosing, combination strategies with existing therapies, and potential use in related sleep disorders beyond NT1. An ICER report from June 2026 suggests oveporexton may offer superior health benefits compared with current treatment options, though pricing and access remain critical considerations.

Implications for Patients, Clinicians, and the Sleep Disorders Field

What do these results mean in practical terms? For people living with narcolepsy type 1-and the clinicians who treat them-oveporexton could reshape the treatment landscape in several concrete ways.

• A new treatment algorithm: An oral orexin receptor 2 agonist may serve as a first-line disease-targeted therapy once approved, potentially becoming the first orexin therapy integrated into standard sleep medicine practice for NT1.

• Simpler regimens: Because restoration of orexin signaling addresses excessive daytime sleepiness, cataplexy, and sleep fragmentation simultaneously, oveporexton could reduce the need for complex polypharmacy that many patients currently manage.

• Diagnostic precision: For clinicians, integrating oveporexton will require accurate differentiation of narcolepsy type 1 vs type 2, relying on orexin levels, HLA genotyping, and clinical assessment. Monitoring response across multiple domains-not just ESS scores-will be essential.

• Access and education: Health system considerations include reimbursement for a rare-disease therapy, education for both sleep medicine specialists and primary care providers, and ensuring equitable availability across patient populations.

Orexin receptor therapies, led by oveporexton (TAK-861), represent a paradigm shift from symptomatic management toward mechanism-based treatment in the sleep disorders field-one that addresses the underlying cause rather than masking its consequences.

FAQ

These questions address common points not fully covered in the sections above.

Is oveporexton (TAK-861) approved yet for narcolepsy type 1?

As of mid-2026, oveporexton is not yet commercially available and remains under regulatory review. The FDA PDUFA target date falls in Q3 2026. Access is currently limited to participants in ongoing clinical trials or compassionate-use programs where available. Clinicians should continue to rely on existing approved therapies until formal approvals are granted, while staying informed about regulatory milestones through Takeda's official communications.

How does TAK-861 differ from sodium oxybate in treating narcolepsy?

Sodium oxybate is a nighttime medication that consolidates sleep and reduces cataplexy through GABA-related mechanisms, whereas TAK-861 is an oral orexin receptor 2 agonist that directly addresses the underlying orexin deficiency during the daytime. Dosing schedules, mechanisms, and side-effect profiles differ substantially. Head-to-head trials have not been completed, so initial treatment decisions will rely on indirect comparisons and clinician judgment.

Will TAK-861 also be used for narcolepsy type 2 or idiopathic hypersomnia?

The current Phase 3 program and regulatory submissions focus exclusively on narcolepsy type 1, where orexin deficiency is well established. Other orexin agonists in Takeda's pipeline, including TAK-360, are being studied for narcolepsy type 2 and idiopathic hypersomnia. Future data from these programs will determine whether TAK-861 or related agents are appropriate for those conditions.

What monitoring will patients on oveporexton likely need?

Clinicians will probably monitor daytime sleepiness via tools like the wakefulness test and Epworth Sleepiness Scale, cataplexy frequency, nighttime sleep quality, mood, and potential side effects such as insomnia or urinary symptoms-particularly during the first weeks of therapy. Longer-term follow-up may include periodic cardiovascular and metabolic assessments, as well as evaluation of interactions with concomitant medications.

Where can clinicians find the latest orexin data on TAK-861?

Clinicians should look for updated clinical trial results and orexin receptor 2 data in major peer-reviewed journals (including the New England Journal and specialty sleep medicine publications), large sleep medicine congress proceedings, and official regulatory documents once available. Takeda's medical information and investor relations websites provide links to key presentations, including a September 2025 investor webcast detailing Phase 3 oveporexton results and market outlook.

Frequently Asked Questions

What is TAK-861 (oveporexton) and how does it work?

TAK-861 is an investigational oral medication that selectively activates orexin receptor 2. It is designed to replace the missing orexin signal in narcolepsy type 1 by stimulating the brain pathways that regulate wakefulness and prevent inappropriate sleep episodes.

How is TAK-861 different from current narcolepsy treatments?

Current treatments like stimulants and sodium oxybate manage symptoms without addressing the underlying cause. TAK-861 targets the root problem by restoring orexin signaling, potentially offering a different approach than existing medications.

What were the results of the Phase 3 clinical trials?

The FirstLight and RadiantLight trials reported positive results across primary and secondary endpoints, including improvements in excessive daytime sleepiness, cataplexy rate, and quality of life measures over 12 weeks of treatment.

What is the current regulatory status of TAK-861?

The FDA granted priority review for TAK-861's new drug application with a target decision date in the third quarter of 2026. Regulatory submissions are also under review in Japan, China, and other markets.

Why is orexin receptor 2 specifically targeted for narcolepsy type 1?

In narcolepsy type 1, orexin-producing neurons are destroyed, causing near-complete orexin loss. Orexin receptor 2 is particularly important for maintaining wakefulness and preventing inappropriate REM sleep, making it the primary target for treatment.